{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Chemed Corp.
Chemed Corp. Hits New 52-Week High at USD 516.53
Chemed Corp. achieved a new 52-week high of USD 516.53, reflecting its notable presence in the hospital industry as a small-cap company with a market cap of approximately USD 12.84 billion. The company maintains strong financial metrics, including a P/E ratio of 48.00 and a return on equity of 27.10%.
Chemed Corp. Hits New 52-Week High at $495.83, Marking Key Milestone
Chemed Corp. has achieved a new 52-week high, reflecting its activity in the hospital industry as a small-cap company. Despite a decline in 1-year performance, the company maintains a strong balance sheet, notable return on equity, and a premium valuation compared to its peers.
Chemed Corp. Hits New 52-Week High at USD 493.05
Chemed Corp. has achieved a new 52-week high, reflecting significant activity in the hospital industry. Despite a decline in 1-year performance, the company maintains a high P/E ratio and strong return on equity, alongside a low dividend yield and conservative debt-to-equity ratio, indicating a complex financial landscape.
Chemed Corp. Stock Hits Day Low of $385 Amid Price Pressure
Chemed Corp., a small-cap hospital industry player, has faced significant stock volatility, with a notable decline over various timeframes. Despite a high return on equity and low debt-to-equity ratio, concerns arise regarding its elevated valuation and modest growth in net sales and operating profit over the past five years.
Chemed Corp. Faces Weak Start with 14% Gap Down Amid Market Concerns
Chemed Corp., a small-cap hospital industry player, experienced a notable decline in its stock performance, reflecting broader market volatility. The company has faced negative trends over the past month and shows mixed technical indicators. Financially, it holds a market cap of around USD 16.75 billion and a price-to-earnings ratio of 55.00.
Chemed Corp. Stock Plummets to New 52-Week Low at $385.00
Chemed Corp., a small-cap hospital industry player, has reached a new 52-week low, reflecting a 27.2% decline over the past year. Despite challenges, it holds a market capitalization of USD 16,753 million, a high return on equity of 25.88%, and a premium valuation compared to peers.
Chemed Corp. Experiences Revision in Stock Evaluation Amid Mixed Market Signals
Chemed Corp., a small-cap hospital industry player, has experienced stock fluctuations, with a current price of $436.78. The company has faced challenges, underperforming the S&P 500 over the past year and year-to-date. Technical indicators present mixed signals, suggesting a cautious outlook for the stock.
Is Chemed Corp. technically bullish or bearish?
As of October 24, 2025, Chemed Corp. is in a bearish trend, indicated by bearish daily moving averages and Bollinger Bands, with mixed signals from MACD and KST, and has significantly underperformed the S&P 500 with a year-to-date return of -17.59%.
Is Chemed Corp. technically bullish or bearish?
As of October 24, 2025, Chemed Corp. is in a bearish trend with moderate strength, underperforming the S&P 500 significantly, showing a year-to-date return of -17.59% compared to the S&P 500's 15.47%.
Is Chemed Corp. technically bullish or bearish?
As of October 24, 2025, Chemed Corp. is in a bearish trend with moderate strength, indicated by negative daily moving averages and Bollinger Bands, and has significantly underperformed the S&P 500 with a year-to-date return of -17.59% compared to the S&P's 15.47%.
Is Chemed Corp. overvalued or undervalued?
As of October 17, 2025, Chemed Corp. is considered very expensive and overvalued with a P/E ratio of 65 and an EV to EBITDA of 44.10, significantly higher than industry averages, while underperforming the S&P 500 with a year-to-date return of -16.84%.
Chemed Corp. Experiences Revision in Stock Evaluation Amidst Competitive Hospital Sector Dynamics
Chemed Corp., a small-cap hospital industry player, has adjusted its valuation metrics, showing a high P/E ratio of 65 and a price-to-book value of 16.99. The company demonstrates strong profitability with a ROCE of 37.01% and ROE of 26.14%, though its low dividend yield of 0.15% may affect investor perception.
Is Chemed Corp. overvalued or undervalued?
As of October 17, 2025, Chemed Corp. is considered overvalued with a high P/E ratio of 65, a PEG ratio of 6.80, and a year-to-date return of -16.84%, significantly underperforming its peers and the S&P 500.
Is Chemed Corp. overvalued or undervalued?
As of October 17, 2025, Chemed Corp. is considered very expensive and overvalued, with a P/E ratio of 65 and significant declines in performance, showing a year-to-date return of -16.84% compared to the S&P 500's gain of 13.30%.
Is Chemed Corp. technically bullish or bearish?
As of September 10, 2025, Chemed Corp. is in a bearish trend, supported by negative indicators like a bearish MACD and KST, and has underperformed the S&P 500 with a year-to-date return of -13.51% compared to the S&P 500's 12.22%.
Is Chemed Corp. overvalued or undervalued?
As of July 29, 2025, Chemed Corp. is considered overvalued with a high P/E ratio of 65 and significant underperformance, showing a year-to-date return of -13.51% compared to the S&P 500's 12.22%.
Is Chemed Corp. technically bullish or bearish?
As of June 20, 2025, Chemed Corp's technical outlook is bearish, supported by bearish MACD, Bollinger Bands, and moving averages across various timeframes, despite a mildly bullish signal from Dow Theory on the monthly chart.
Is Chemed Corp. overvalued or undervalued?
As of June 10, 2025, Chemed Corp. is considered overvalued with a P/E ratio of 65, significantly higher than its peers, and despite a YTD return of 4.11%, it has underperformed the S&P 500's 2.44% return.
Who are in the management team of Chemed Corp.?
As of March 2022, the management team of Chemed Corp. includes Mr. Kevin McNamara (CEO), Mr. George Walsh (Independent Chairman), and several independent directors: Mr. Thomas Hutton, Mr. Joel Gemunder, Mr. Patrick Grace, Mr. Walter Krebs, and Dr. Andrea Lindell.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
